Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis

•MDR-TB is difficult to manage; updated clinical guidance of new drug use is needed•No recent systematic review/meta-analysis on delamanid (DLM) is available•In observational studies including DLM (591 patients) the success rate was 80.9%•In experimental studies including DLM (391 patients) the succ...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	International journal of infectious diseases Ročník 124; číslo Suppl 1; s. S90 - S103
Hlavní autori:	Nasiri, Mohammad Javad, Zangiabadian, Moein, Arabpour, Erfan, Amini, Sirus, Khalili, Farima, Centis, Rosella, D'Ambrosio, Lia, Denholm, Justin T., Schaaf, H. Simon, van den Boom, Martin, Kurhasani, Xhevat, Dalcolmo, Margareth Pretti, Al-Abri, Seif, Chakaya, Jeremiah, Alffenaar, Jan-Willem, Akkerman, Onno, Silva, Denise Rossato, Muňoz-Torrico, Marcela, Seaworth, Barbara, Pontali, Emanuele, Saderi, Laura, Tiberi, Simon, Zumla, Alimuddin, Migliori, Giovanni Battista, Sotgiu, Giovanni
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Canada Elsevier Ltd 01.11.2022 Elsevier
Predmet:	Antitubercular Agents - therapeutic use bedaquiline delamanid Diarylquinolines - therapeutic use effectiveness Humans MDR-TB Nitroimidazoles - therapeutic use Oxazoles - adverse effects safety Treatment Outcome Tuberculosis, Multidrug-Resistant - drug therapy effectiveness MDR-TB delamanid bedaquiline safety TB
ISSN:	1201-9712, 1878-3511, 1878-3511
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!